Contributions of B12_Bettina

Contributions by B12_Bettina, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,166 edits includes activity predating the current log.

1. 10:31, 25 Apr 2026 (diff | hist) Zhuhai Kerui Biotechnology 14,711 ±0 expand §Corporate identity and history
2. 03:39, 27 Mar 2026 (diff | hist) Grey market 4,279 ±0 m expand §What the term does not mean
3. 04:52, 9 Oct 2025 (diff | hist) Tianjin Finder Chemical 13,749 +226 correct the regional-warehouse list — six sites, not five
4. 12:58, 2 Aug 2025 (diff | hist) SURMOUNT trial programme 4,721 +149 the percentage quoted was placebo-adjusted; label it
5. 01:00, 24 Jul 2025 (diff | hist) Sarcopenia 3,762 ±0 state whether the figure is a mean or a median
6. 10:55, 30 Jun 2025 (diff | hist) Flourishglobal Peptide Biotech 7,214 +330 label the reception tally as weak, self-selected evidence at this point of use
7. 03:15, 3 Jun 2025 (diff | hist) Haemoglobin A1c 4,096 +700 m split the analytical performance from the clinical interpretation
8. 21:16, 1 Apr 2025 (diff | hist) Haemoglobin A1c 3,366 ±0 m state which fraction the assay actually measures
9. 02:35, 16 Mar 2025 (diff | hist) Fasting insulin 2,962 ±0 split the analytical performance from the clinical interpretation
10. 15:09, 24 Feb 2025 (diff | hist) Fasting insulin 2,962 ±0 m expand §Behaviour under treatment
11. 04:25, 24 Feb 2025 (diff | hist) Sarcopenia 2,738 ±0 split the analytical performance from the clinical interpretation
12. 12:49, 9 Jan 2025 (diff | hist) Haemoglobin A1c 3,218 ±0 copyedit
13. 13:43, 6 Jan 2025 (diff | hist) ChinaPeptides 5,517 +185 add the research-use-only statement to the lead rather than only the footer
14. 17:57, 27 Dec 2024 (diff | hist) Regulatory status by jurisdiction 2,721 ±0 add category for drug regulation
15. 05:18, 3 Aug 2024 (diff | hist) Nantong Guangyuan Chemical 1,996 ±0 add the see-also to the certificate-of-analysis article